ERBB2 and breast carcinoma: In the phase 1b clinical trial (NCT03767335), HER2+ advanced breast cancer patients with the PIK3CA mutant received MEN1611 plus only trastuzumab (Group A) or MEN1611 plus trastuzumab and fulvestrant (Group B).